Hematology and Hemotherapy Center, University of Campinas, Campinas, SP, Brazil.
Haemophilia. 2012 May;18(3):e188-91. doi: 10.1111/j.1365-2516.2012.02769.x. Epub 2012 Feb 22.
Acquired von Willebrand syndrome (AVWS) is a rare hemorrhagic condition for which very little information is available regarding the management of extreme challenges to Haemostasis. The AVWS is more common in the elderly, who are frequently exposed to invasive procedures and/or chemotherapy. Haematopoietic stem cell transplantation (HSCT) is a situation in which the haemostatic capacity is challenged by severe thrombocytopaenia, chemotherapy-associated mucosal barrier breakdown and the need for invasive procedures. In our report, we present and discuss the haemostatic management of a patient with AVWS who was refractory to Von Willebrand factor concentrate replacement during the course of an autologous HSCT to treat multiple myeloma. Patients with AVWS are frequently exposed to high-risk haemostatic challenges, and additional information about the haemostatic management of these situations is necessary.
获得性血管性血友病综合征(AVWS)是一种罕见的出血性疾病,关于其对止血的极端挑战的管理,几乎没有信息。AVWS 在老年人中更为常见,他们经常接受有创性操作和/或化疗。造血干细胞移植(HSCT)是一种严重血小板减少、化疗相关黏膜屏障破坏和需要有创性操作的情况下,对止血能力构成挑战的情况。在我们的报告中,我们介绍并讨论了一名 AVWS 患者的止血管理,该患者在接受自体 HSCT 治疗多发性骨髓瘤的过程中对血管性血友病因子浓缩物替代治疗有反应。AVWS 患者经常面临高风险的止血挑战,因此需要更多关于这些情况的止血管理信息。